

Genesis Biotech Inc.

website: http://www.genesisbio.com.tw e-mail: info@genesisbio.com.tw

Anti-SARS-CoV Spike Protein, Rabbit-Polyclonal Antibody

Catalog No. GB-10311M Quantity: 250 µl Antigen species: Synthetic SARS-CoV peptide

Reactivity: SARS-CoV Applications tested: ELISA, epitope mapping

Host species: rabbit Type: polyclonal antibodies Form: lyophilized serum

Target description

Severe Acute Respiratory Syndrome (SARS), an 1. emerging disease characterized by atypical pneumonia, has recently been attributed to a 2. novel coronavirus (SARS-CoV). The spike (S) protein was one of the structural proteins of 3. SARS-CoV (N, S, sE, M), which epitopes were defined by parallel comparison of SARS-CoV 4. infected and non-infected human sera with EpitoscreenTM peptide array. The S glycoprotein 5. of SARS-CoV is not only responsible for receptor binding and virus fusion, but also a major 6. antigen among the SARS-CoV proteins that induces protective antibody responses.

Antigen

This polyclonal antibody was raised by immunizing rabbit with synthetic peptide mixture containing amino acids on the N-terminal domain (55-94) of spike protein (S) of SARS-CoV. The antigen contained the epitope defined by EpitoscreenTM peptide array (Genesis Biotech Inc.).

Application

The antibody specificity was assayed by ELISA with the synthetic peptide antigen of spike protein of SARS-CoV, which epitopes were defined by parallel comparison of SARS-CoV infected and non-infected human sera. The antibody titer is more than 50K for ELISA. It has not been tested in the other applications. However, for the first testing, we recommend 1/5,000 dilution for ELISA, 1/1000 dilution for Western blot analysis (WB) of recombinant protein, 1/400 dilution for tissue extracts or cell lysates, 1/100 dilution for immunohistochemistry (IHC) staining on frozen cryosections or paraffin embedded sections.

coated	GA311		GA312		GA337	
Ab dilution	prebleed	Anti- serum	prebleed	Anti- serum	prebleed	Anti- serum
1:0.1K	1.089	2.676	0.710	2.067	0.793	2.558
1:1K	0.378	2.001	0.234	1.071	0.227	2.218
1:10K	0.139	0.601	0.098	0.234	0.086	0.759
1:100K	0.109	0.173	0.077	0.151	0.067	0.179
1:1,000K	0.107	0.116	0.073	0.102	0.067	0.124
Titer		~88.8K		~91.6K		~831K

Related Products

- Severe Acute Respiratory Syndrome (SARS), an 1. Anti-SARS-CoV N protein rabbit mAb (GB-emerging disease characterized by atypical 61170)
 - Anti-SARS-CoV N protein rabbit pAb (GB-10168M)
 - 3. Anti-SARS-CoV protein X2 (3b) rabbit pAb (GB- 10230M)
 - Anti-SARS-CoV spike protein rabbit pAb (GB- 10311M)
 - Anti-SARS- CoV spike protein rabbit pAb (GB- 10314M)
 - Anti-SARS- CoV spike protein rabbit pAb (GB- 10326M)
 - 7. Anti-SARS- CoV spike protein rabbit pAb (GB- 10333M)
 - 8. Anti-SARS- CoV 3CL mouse mAb (PG-20001)

Storage

It is supplied as lyophilized antiserum of polyclonal antibody. Rehydrate the lyophilized powder with 250 μ l sterile water will have the same concentration with original antiserum. Store at 4°C for short term application. For long-term storage, aliquot and store at -20°C.

References

- Huang JP, Chen LH. The epitope profile of the SARS-CoV infected and non-infected sera. US Patent and Taiwan Patent pending (2003).
- Buchholz UJ, Bukreyev A, Yang L, Lamirande EW, Murphy BR, Subbarao K, Collins PL. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9804-9. Epub 2004 Jun 21.
- He Y, Zhou Y, Wu H, Luo B, Chen J, Li W, Jiang S. Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines. J Immunol. 2004 Sep 15;173(6):4050-7.